Neurodexis11 Therapeutics

Neurodexis11 Therapeutics is an early-stage biotechnology company focused on developing first-in-class epigenetic therapies for Alzheimer's disease and other central nervous system (CNS) disorders. The company's proprietary therapeutic platform targets Histone Deacetylase 11 (HDAC11), an epigenetic regulator linked to neuroinflammation and Alzheimer's pathology. Its lead candidate, PB151, is a highly selective, brain-penetrant, and orally bioavailable small molecule inhibitor designed to deliver disease-modifying effects without the off-target toxicity associated with broad-spectrum HDAC drugs. Backed by strong translational data in Alzheimer's models and human cells, Neurodexis11 is advancing PB151 toward IND-enabling studies while exploring potential pipeline expansions into Parkinson's disease, chronic pain, and oncology.